- Home
- JANX vs IRON Comparison
JANX vs IRON Comparison
Compare JANX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- IRON
- Stock Information
- Founded
- JANX 2017
- IRON 2017
- Country
- JANX United States
- IRON United States
- Employees
- JANX N/A
- IRON N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- IRON Health Care
- Exchange
- JANX Nasdaq
- IRON Nasdaq
- Market Cap
- JANX 2.2B
- IRON 1.9B
- IPO Year
- JANX 2021
- IRON N/A
- Fundamental
- Price
- JANX $26.81
- IRON $47.15
- Analyst Decision
- JANX Strong Buy
- IRON Strong Buy
- Analyst Count
- JANX 8
- IRON 10
- Target Price
- JANX $91.25
- IRON $83.80
- AVG Volume (30 Days)
- JANX 784.7K
- IRON 374.7K
- Earning Date
- JANX 05-06-2025
- IRON 05-08-2025
- Dividend Yield
- JANX N/A
- IRON N/A
- EPS Growth
- JANX N/A
- IRON N/A
- EPS
- JANX N/A
- IRON N/A
- Revenue
- JANX $10,588,000.00
- IRON N/A
- Revenue This Year
- JANX N/A
- IRON N/A
- Revenue Next Year
- JANX $289.47
- IRON N/A
- P/E Ratio
- JANX N/A
- IRON N/A
- Revenue Growth
- JANX 30.99
- IRON N/A
- 52 Week Low
- JANX $26.39
- IRON $25.64
- 52 Week High
- JANX $71.71
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- JANX 29.87
- IRON 28.58
- Support Level
- JANX $29.77
- IRON $51.57
- Resistance Level
- JANX $32.00
- IRON $53.61
- Average True Range (ATR)
- JANX 1.44
- IRON 2.07
- MACD
- JANX -0.00
- IRON -0.38
- Stochastic Oscillator
- JANX 7.01
- IRON 1.73
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.